1-20 of 23
Frank G. Haluska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Clinical Trials & Observations
Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
Journal: Blood
Blood (2018) 132 (4): 393–404.
https://doi.org/10.1182/blood-2016-09-739086
Published: 2018
Includes: Supplemental data
Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Clinical Trials & Observations
Michael W. Deininger, J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, Jin Li, Wendy T. Parker, Stephanie Lustgarten, Tim Clackson, Frank G. Haluska, Francois Guilhot, Hagop M. Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P. Hughes, Victor M. Rivera, Susan Branford
Journal: Blood
Blood (2016) 127 (6): 703–712.
https://doi.org/10.1182/blood-2015-08-660977
Published: 2016
Includes: Supplemental data
Journal Articles

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Moshe Yair Levy, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Mo Yang, PhD, Frank G. Haluska, MD
Journal: Blood
Blood (2015) 126 (23): 1588.
https://doi.org/10.1182/blood.V126.23.1588.1588
Published: 2015
Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera
Journal: Blood
Blood (2014) 124 (21): 3153.
https://doi.org/10.1182/blood.V124.21.3153.3153
Published: 2014
Journal Articles

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Moshe Yair Levy, MD, Lisa J McGarry, MPH, Hui Huang, PhD MBA, Stephanie Lustgarten, PhD, Christopher Nieset, PharmD, Frank G Haluska
Journal: Blood
Blood (2014) 124 (21): 3154.
https://doi.org/10.1182/blood.V124.21.3154.3154
Published: 2014
Journal Articles

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp Le Coutre, Ronald Paquette, Charles Chuah, MD, Franck E. Nicolini, Jane F. Apperley, MD, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
Journal: Blood
Blood (2014) 124 (21): 3135.
https://doi.org/10.1182/blood.V124.21.3135.3135
Published: 2014
Journal Articles

Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients

Ronald Knickerbocker, David J. Dorer, Frank G. Haluska, Michele Baccarani, Jorge E. Cortes, MD, Andreas Hochhaus, MD, Moshe Talpaz
Journal: Blood
Blood (2014) 124 (21): 4546.
https://doi.org/10.1182/blood.V124.21.4546.4546
Published: 2014
Journal Articles

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

Michael J. Mauro, Jorge E. Cortes, MD, Andreas Hochhaus, Michele Baccarani, Timothy P. Hughes, Francois Guilhot, Michael W. Deininger, Hagop M. Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, Tim Clackson, Moshe Talpaz
Journal: Blood
Blood (2014) 124 (21): 4552.
https://doi.org/10.1182/blood.V124.21.4552.4552
Published: 2014
Journal Articles

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Moshe Talpaz, Jorge E. Cortes, Hagop Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Thomas O'Hare, PhD, Simin Hu, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian J. Druker, Michael W. Deininger, Michael J. Mauro, MD
Journal: Blood
Blood (2014) 124 (21): 4558.
https://doi.org/10.1182/blood.V124.21.4558.4558
Published: 2014
Journal Articles

Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib

Martin C. Mueller, Michele Baccarani, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Frank G. Haluska, Jorge E. Cortes, MD
Journal: Blood
Blood (2014) 124 (21): 518.
https://doi.org/10.1182/blood.V124.21.518.518
Published: 2014
Journal Articles

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Jeffrey H. Lipton, Charles Chuah, Agnes Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E. Nicolini, Philipp Le Coutre, Richard Clark, Leif Stenke, David Andorsky, Vivian Oehler, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Frank G Haluska, Michele Baccarani, Jorge E. Cortes, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Hagop M. Kantarjian, MD, Neil P. Shah, Moshe Talpaz, Michael W. Deininger
Journal: Blood
Blood (2014) 124 (21): 519.
https://doi.org/10.1182/blood.V124.21.519.519
Published: 2014
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D. le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F. Apperley, MD, H Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, Frank G. Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M. Goldman, MD, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2738.
https://doi.org/10.1182/blood.V122.21.2738.2738
Published: 2013
Journal Articles

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Javier Pinilla-Ibarz, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Philipp D. Le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2013) 122 (21): 4007.
https://doi.org/10.1182/blood.V122.21.4007.4007
Published: 2013
Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Philipp D. Le Coutre, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. Dipersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Kumiko Yanase, MD, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, DM, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1496.
https://doi.org/10.1182/blood.V122.21.1496.1496
Published: 2013
Journal Articles

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Andreas Hochhaus, MD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Michael W. Deininger, MD, PhD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD, François Guilhot, MD
Journal: Blood
Blood (2013) 122 (21): 1498.
https://doi.org/10.1182/blood.V122.21.1498.1498
Published: 2013
Journal Articles

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Philipp D le Coutre, MD, Ronald Paquette, MD, Charles Chuah, MD, Franck E. Nicolini, MD PhD, Jane F Apperley, MD, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J DeAngelo, MD, PhD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C. Müller, MD, Carlo Gambacorti-Passerini, MD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, François Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil P. Shah, MD, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 650.
https://doi.org/10.1182/blood.V122.21.650.650
Published: 2013
Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Michael W. Deininger, MD, PhD, Neil P. Shah, MD, PhD, Jorge E. Cortes, MD, Dong-Wook Kim, MD, PhD, Franck E. Nicolini, MD, PhD, Moshe Talpaz, MD, Michele Baccarani, MD, Martin C Muller, MD, Jin Li, Stephanie Lustgarten, PhD, Tim Clackson, PhD, Christopher D Turner, MD, Frank G Haluska, MD, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Francois Guilhot, MD, John M Goldman, DM, Hagop M. Kantarjian, MD, Simona Soverini, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD
Journal: Blood
Blood (2013) 122 (21): 652.
https://doi.org/10.1182/blood.V122.21.652.652
Published: 2013
Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ron Paquette, MD, PhD, Charles Chuah, MD, Franck E Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M Kantarjian, M.D., The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 163.
https://doi.org/10.1182/blood.V120.21.163.163
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Hagop M. Kantarjian, MD, Dong-Wook Kim, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, MD, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John Goldman, DM, FRCP, FRCPath, FMedSci, Neil Shah, MD, PhD, Jorge E. Cortes, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 915.
https://doi.org/10.1182/blood.V120.21.915.915
Published: 2012
Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Dong-Wook Kim, Jorge E. Cortes, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ronald Paquette, MD, PhD, Charles Chuah, MD, Franck E. Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel DeAngelo, MD, Elisabetta Abruzzese, MD, PhD, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, MD, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M. Kantarjian, MD, The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 3749.
https://doi.org/10.1182/blood.V120.21.3749.3749
Published: 2012